Vol. 2 No. 11 (2022)
Reimbursement Recommendations

Cabozantinib (Cabometyx)

Published November 17, 2022

Key Messages

  • CADTH recommends that Cabometyx should be reimbursed by public drug plans for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) if certain conditions are met.
  • Cabometyx should only be covered to treat patients who did not respond to prior radioactive iodine (RAI) therapy or are not eligible for RAI, those previously treated with 1 to 2 tyrosine kinase inhibitors (TKIs), and those who have good performance status (i.e., they are in relatively good health).
  • Cabometyx should only be reimbursed if it is prescribed by specialists with experience in the management of thyroid cancer and the cost of Cabometyx is reduced.